Answers are grounded in this paper and cite their sources.
Graft-versus-host disease (GVHD) is a complication seen in allogeneic stem cell transplantation. The incidence and severity is more in T-cell replete allograft (stem cells), donor T-cells being the principal mediators of GVHD. Acute GVHD is seen within 90 days post transplant and chronic GVHD after 90 days. Cyclosporin A (CsA) and methotrexate combination is used in prevention of acute GVHD. Corticosteroids and CsA combination is used in treatment of both acute and chronic GVHD.
No takes yet. Share an insight, caveat, or question.
SVSS Prasad (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: